Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. Lung Cancer: ALK Gene Rearranged Non-Small Cell Lung Cancer Regimen: Ceritinib. Hematology-Oncology Therapy Updates, 26 July 2018. McGraw-Hill, 2018. AccessHemOnc. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428273§ionid=194479786APA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. (2018). Lung cancer: alk gene rearranged non-small cell lung cancer regimen: ceritinib. Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. Hematology-oncology therapy updates. McGraw-Hill. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428273§ionid=194479786.MLA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. "Lung Cancer: ALK Gene Rearranged Non-Small Cell Lung Cancer Regimen: Ceritinib." Hematology-Oncology Therapy Updates Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. McGraw-Hill, 2018, https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=428273§ionid=194479786. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Lung Cancer: ALK Gene Rearranged Non-Small Cell Lung Cancer Regimen: Ceritinib by Hematology-Oncology Therapy Listen + +Update to Chapter 22: Lung Cancer + Shaw AT et al. N Engl J Med. 2014;370(13):1189–1197 Cho BC et al. J Thorac Oncol. 2017;12(9):1357–1367 FDA and EMA prescribing information and miscellaneous sources Ceritinib 450 mg/dose; administer orally once daily, continually, with food (total dose/week = 3150 mg) Notes: On December 21, 2017, the U.S. FDA revised the approved dosage regimen to 450 mg administered orally once daily with food based on similar systemic exposure and improved gastrointestinal tolerability compared to the 750-mg dose administered without food found in the ASCEND-8 study. The study found similar systemic exposure between the 450 mg (fed state) and 750 mg (fasting state) regimens, but improved gastrointestinal tolerability with the former Patients who delay taking ceritinib at a regularly scheduled time may take a missed dose if the interval remaining before the next regularly scheduled dose is ≥12 hours. If vomiting occurs after a dose of ceritinib, take the next dose at the next regularly scheduled time In patients with a history of diabetes mellitus, optimize antihyperglycemic medications prior to initiating ceritinib. If ceritinib therapy is interrupted, patients receiving antihyperglycemic medications should be monitored for hypoglycemia Ceritinib is metabolized by cytochrome P450 (CYP) CYP3A subfamily enzymes. Avoid using ceritinib with strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin) when possible. If concurrent use with a strong CYP3A4 inhibitor is required, reduce the ceritinib dose by approximately 33%. Avoid using ceritinib with strong CYP3A4 inducers (eg, carbamazepine, rifampin, phenytoin, phenobarbital, St John’s wort). Advise patients to not consume grapefruit and grapefruit juice as they may inhibit CYP3A in the gut wall and increase the bioavailability of ceritinib Ceritinib may inhibit CYP3A4 and CYP2C9; use caution and consider dose reduction, when appropriate, of concurrently used CYP3A4 and CYP2C9 substrates, especially if the substrate has a narrow therapeutic index (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, warfarin, phenytoin) Supportive Care Antiemetic prophylaxis Emetogenic potential is MODERATE See Chapter 39 for antiemetic recommendations Hematopoietic growth factor (CSF) prophylaxis Primary prophylaxis is NOT indicated See Chapter 43 for more information Antimicrobial prophylaxis Risk of fever and neutropenia is LOW Antimicrobial primary prophylaxis to be CONSIDERED: Antibacterial—not indicated Antifungal—not indicated Antiviral—not indicated unless patient previously had an episode of HSV See Chapter 47 for more information Diarrhea management Latent or delayed onset diarrhea: Loperamide 4 mg orally initially after the first loose or liquid stool, then Loperamide 2 mg orally every 2 hours during waking hours, plus Loperamide 4 mg orally every 4 hours during hours of sleep Continue for at least 12 hours after diarrhea resolves Recurrent diarrhea after a 12-hour diarrhea-free interval is treated as a new episode Rehydrate orally with fluids and electrolytes during a diarrheal episode If a patient develops blood or mucus in stool, dehydration, or hemodynamic instability, or if diarrhea persists <48 hours despite loperamide, stop loperamide and hospitalize the patient for IV hydration Alternatively, a trial of diphenoxylate hydrochloride 2.5 mg with atropine sulfate 0.025 mg (eg, Lomotil) Initial adult dose is 2 tablets 4 times daily until control has been achieved, after which the dose may be reduced to meet individual requirements. Control may often be maintained with as little as 2 tablets daily Clinical improvement of acute diarrhea is usually observed within 48 hours. If improvement of chronic diarrhea after treatment with a maximum daily dose of 8 tablets is not observed within 10 days, control is unlikely with further administration Persistent diarrhea: Octreotide 100–150 mcg subcutaneously 3 times daily. Maximum total daily dose is 1500 mcg Antibiotic therapy during latent or delayed onset diarrhea: A fluoroquinolone (eg, ciprofloxacin 500 mg orally every 12 hours) if absolute neutrophil count <500/mm3 with or without accompanying fever in association with diarrhea Antibiotics should also be administered if patient is hospitalized with prolonged diarrhea and should be continued until diarrhea resolves + +Patient Population Studied + A phase 1 study involved 130 patients with locally advanced or metastatic, ALK-rearranged, cancer. The majority of patients (122; 94%) had advanced NSCLC. Eligible patients were aged ≥18 years, with an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2. A total of 59 patients underwent a dose-escalation phase. An additional 71 patients were then treated at the maximum tolerated dose (750 mg daily) determined in the dose-escalation phase + +Efficacy (N = 122) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Overall response rate✫ 58% Overall response rate✫ for patients who received 750 mg daily 59% ✫Overall response rate is the percentage of patients who experienced a confirmed partial or complete response to the study drug Note: Results are shown for the patients with advanced NSCLC. Of the 8 patients who had other types of advanced cancer, 2 had a response to the study drug + +Therapy Monitoring + Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, or fluid replacement, as indicated Monitor with liver laboratory tests including ALT, AST, and total bilirubin once a month and as clinically indicated, with more frequent testing in patients who develop transaminase elevations Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis Obtain an ECG and evaluate electrolytes at baseline. Conduct periodic monitoring with ECGs and electrolytes in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or those who are taking medications that are known to prolong the QTc interval. Monitor fasting serum glucose prior to the start of ceritinib treatment and periodically thereafter as clinically indicated Monitor lipase and amylase prior to the start of ceritinib treatment and periodically thereafter as clinically indicated + +Treatment Modifications + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Starting dose = 450 mg once daily with food Dose levels 450 mg / 300 mg / 150 mg Adverse Event Treatment Modification ≥G3 ALT or AST elevation (>5× ULN) + total bilirubin ≤2× ULN Withhold ceritinib until recovery to baseline or ALT and AST ≤3× ULN, then resume ceritinib but reduce the dose by 150 mg ≥G2 ALT or AST elevation [>3× ULN] + total bilirubin >2× ULN Permanently discontinue ceritinib Any grade treatment-related ILD/pneumonitis Permanently discontinue ceritinib Severe or intolerable nausea, vomiting or diarrhea despite optimal antiemetic or antidiarrheal therapy Withhold until improved, then resume ceritinib but reduce the dose by 150 mg Persistent hyperglycemia >250 mg/dL despite optimal antihyperglycemic therapy Withhold ceritinib until hyperglycemia is adequately controlled, then resume ceritinib but reduce the dose by 150 mg. If adequate hyperglycemic control cannot be achieved with optimal medical management, discontinue ceritinib G3 lipase or amylase elevation [>2× ULN] Withhold ceritinib and monitor serum lipase and amylase. After recovery to <1.5× ULN resume ceritinib but reduce the dose by 150 mg Concomitant use of a strong CYP3A inhibitor is unavoidable Reduce the ceritinib dose by ∼1/3, rounded to the nearest multiple of the 150 mg dosage strength. After discontinuation of a strong CYP3A inhibitor, resume the ceritinib dose taken prior to initiating the strong CYP3A4 inhibitor Dose adjustments for cardiac adverse events QTc interval >500 msec on ≥2 separate ECGs Withhold ceritinib until QTc interval <481 msec or recovery to baseline if baseline QTc ≥481 msec, then resume ceritinib but reduce the dose by 150 mg QTc interval prolongation in combination with torsades de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia Permanently discontinue ceritinib Symptomatic bradycardia that is not life-threatening Withhold ceritinib until recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm. Evaluate concomitant medications known to cause bradycardia. Resume ceritinib but reduce the dose by 150 mg Clinically significant bradycardia requiring intervention or life-threatening bradycardia in patients taking a concomitant medication also known to cause bradycardia or a medication known to cause hypotension Withhold ceritinib until recovery to asymptomatic bradycardia or to a heart rate ≥60 bpm. If the concomitant medication can be adjusted or discontinued then resume ceritinib but reduce the dose by 150 mg Life-threatening bradycardia in patients who are not taking a concomitant medication also known to cause bradycardia or known to cause hypotension Permanently discontinue ceritinib Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECG, electrocardiogram; ILD, interstitial lung disease; ULN, upper limit of normal Notes: Advise the use of effective contraception during treatment with ceritinib and for at least 2 weeks following completion of therapy Ceritinib is eliminated primarily via the liver and drug exposure may be increased in patients with hepatic impairment. Patients with mild hepatic impairment do not require dose adjustments. A recommended dose for patients with moderate to severe hepatic impairment has not been determined No dose adjustment is recommended for patients with mild or moderate renal impairment. The safety of alectinib in patients with creatinine clearance <30 mL/min has not been studied + +Adverse Events (N = 130) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Grade 3/4✫ (%) Any event 49 Elevated ALT level 21 Elevated AST level 11 Elevated lipase level 7 Diarrhea 7 Nausea 5 Vomiting 5 Fatigue 5 Hypophosphatemia 3 Elevated amylase level 2 Elevated blood alkaline phosphatase level 2 Hyperglycemia 2 ✫According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 Notes: Only events reported in ≥2% and suspected to be related to the study drug are included in this table. All events were reversible on discontinuation of ceritinib treatment. Four cases of interstitial lung disease and 1 case of asymptomatic grade 3 prolongation of the QT interval were thought to possibly be related to ceritinib treatment. Dose reduction was required in 51% of patients, and permanent discontinuation of the study drug owing to an adverse event occurred in 6% of patients. Of the patients receiving the maximum tolerated dose of 750 mg daily, 62% required dose reduction. No treatment-related deaths occurred.